M

Mankind Pharma Ltd
NSE:MANKIND

Watchlist Manager
Mankind Pharma Ltd
NSE:MANKIND
Watchlist
Price: 2 359.2 INR 0.57% Market Closed
Market Cap: 973.6B INR

Profitability Summary

Mankind Pharma Ltd's profitability score is 64/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

64/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

64/100
Profitability
Score
64/100
Profitability
Score

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Mankind Pharma Ltd

Revenue
116.4B INR
Cost of Revenue
-33.6B INR
Gross Profit
82.8B INR
Operating Expenses
-58.4B INR
Operating Income
24.4B INR
Other Expenses
-4B INR
Net Income
20.4B INR

Margins Comparison
Mankind Pharma Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
IN
Mankind Pharma Ltd
NSE:MANKIND
945.2B INR
71%
21%
18%
US
Eli Lilly and Co
NYSE:LLY
725B USD
82%
40%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
369.3B USD
68%
26%
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
84%
45%
35%
CH
Roche Holding AG
SIX:ROG
212.9B CHF
74%
33%
14%
CH
Novartis AG
SIX:NOVN
188.6B CHF
76%
33%
24%
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP
82%
24%
14%
US
Merck & Co Inc
NYSE:MRK
196.3B USD
78%
34%
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
131.8B USD
75%
27%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Mankind Pharma Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
IN
Mankind Pharma Ltd
NSE:MANKIND
945.2B INR
22%
16%
24%
25%
US
Eli Lilly and Co
NYSE:LLY
725B USD
78%
14%
38%
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
369.3B USD
30%
12%
18%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
88%
27%
70%
30%
CH
Roche Holding AG
SIX:ROG
212.9B CHF
27%
9%
29%
20%
CH
Novartis AG
SIX:NOVN
188.6B CHF
33%
13%
26%
18%
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP
20%
7%
18%
14%
US
Merck & Co Inc
NYSE:MRK
196.3B USD
39%
16%
25%
19%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
131.8B USD
9%
4%
10%
9%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less